Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure

C. J. Hannan, Y. Liang, Jerry David Allison, C. G. Pantazis, J. R. Searle

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Immune deficient mice growing xenografts of HT-29 or A-431 cell lines were treated with cisplatin carboplatin or doxorubicin in combination with one hour of wholebody pulsed magnetic field (PMF) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTesla(rms); pulses rose for 120 μsec and then abruptly fell to neutral and were repeated at a rate of 250 pulses per second). At 24 days the mice in each experiment were found to have significantly (p < 0.05 ANOVA) different tumor sizes among groups. The smallest mean tumor volume was consistently found in the drug + PMF group. With A-431 tumors the cisplatin + PMF group (T) was significantly smaller 52% [1-(100T/C)], than the cisplatin alone group (C). In HT-29 tumors, those treated with carboplatin + PMF had the smallest tumor volume at just 34% of the carboplatin-alone group. In HT-29 tumors, the doxorubicin + PMF group was 35% of the doxorubicin alone group.

Original languageEnglish (US)
Pages (from-to)1521-1524
Number of pages4
JournalAnticancer research
Volume14
Issue number4 A
StatePublished - 1994

Keywords

  • Carboplatin
  • Chemotherapy
  • Cisplatin
  • Doxorubicin
  • Experimental therapeutics
  • Pulsed magnetic field

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure'. Together they form a unique fingerprint.

  • Cite this

    Hannan, C. J., Liang, Y., Allison, J. D., Pantazis, C. G., & Searle, J. R. (1994). Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. Anticancer research, 14(4 A), 1521-1524.